CHRYSO®Quad: A Range of Admixtures and Services for Complex Local Sands and Aggregates, in Support of the Circular Economy
20.4.2023 12:20:00 EEST | Business Wire | Press release
To support sustainable construction stakeholders, CHRYSO is strengthening its CHRYSO®Quad range and associated services in response to the challenges of the circular economy. CHRYSO promotes the use of complex aggregates sourced locally or from recycled concrete from deconstruction sites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005807/en/
CHRYSO®Quad fosters local sourcing of aggregates and sands (Photo: Shutterstock)
Dedicated services to characterize materials and adjust admixture solutions
It all starts with the analysis of sands using the patented CHRYSO®CLEAR Test method, which diagnoses the presence of swelling clay. Then, the dedicated CHRYSO®Quad Lab service allows CHRYSO experts to carry out a precise diagnosis of a series of additional parameters: particle size (to determine the lack or excess of fines), absorption, shape factors, etc.
Additionally, compaction tests are performed in CHRYSO's application laboratories to consider all the parameters of the concrete mix design. Finally, the brand-new digitalized service CHRYSO®Quad App proposes the most suitable admixture solution based on the customer's material characterization (sands and aggregates) and thus broadens the scope of potential supply sources.
The use of complex aggregates and sands while improving concrete performance
The customized CHRYSO®Quad admixture solutions are adjusted according to the available resources of complex sands and aggregates. This allows clients to gain flexibility by integrating new sands and aggregates into their concrete mix and overcome shortages or tensions in material supplies. CHRYSO experts accompany their clients in producing durable and robust concrete that can withstand material variations.
CHRYSO®Quad contributes to the circular economy and reduces the carbon footprint
By anticipating the constraints of quality and availability of local sands and aggregates, CHRYSO®Quad fully embraces a circular economy approach.
CHRYSO®Quad is a development lever for recycling materials from deconstruction, allowing for the recovery and use of recycled aggregates.
The use of local resources also contributes to reducing supply costs and decreasing the carbon footprint associated with the transportation of raw materials.
CHRYSO continues to deploy CHRYSO®Quad
To date, 9 million m3 of concrete have already benefited from CHRYSO®Quad solutions, including on large construction sites around the world. Leveraging its international network of application laboratories, CHRYSO provides answers to the sourcing challenges of aggregates faced by industry stakeholders.
CASE STUDY
With CHRYSO®Quad 870, a concrete industry player manages to use 100% of complex sands in its concrete formulation
To support a client in the south of France in optimizing the sand resources used in its concrete formulation, CHRYSO proposed its CHRYSO®Quad 870 solution, which improved productivity, concrete quality, and allowed for sourcing exclusively from local suppliers.
This industry player supplied his plant with sand from two quarries. A complex crushed sand, sourced from a quarry near the plant. A second "corrective" sand, from another quarry located 60km from the plant. Up to 50% of each sand was used in the different concrete mixes, which ranged from class S3 to S5.
In its specifications, the industry player requested that CHRYSO provides a solution to increase its capacity to use complex sands (with a high content of fines and the presence of clays). Thanks to the CHRYSO®Quad Lab service, sands were recovered and analyzed in the laboratory and in the plants. This allowed CHRYSO to design the customized CHRYSO®Quad 870 product. The first product testing phases were validated on site by sand variability checks carried out by the client using the CHRYSO®CLEAR Test kit.
As a result, the customer has extended the use of CHRYSO®Quad 870 to three other concrete plants and now uses 100% complex sand from a local quarry. The use of a single sand, with a constant dosage, brings a benefit of regularity in the production, reducing the weight of CEM II A cement in the design mix, which represents a 10% reduction of the carbon footprint. In addition, thanks to the exclusive use of short-distance sourcing, 24 lorry journeys per month have been avoided.
ABOUT SAINT-GOBAIN CONSTRUCTION CHEMICALS
Saint-Gobain Construction Chemicals offers cement additives, concrete admixtures and specialty building materials, through the combined activities of Chryso and GCP. Its recent technologies for sustainable construction help reduce energy consumption, lower the carbon footprint of cements and concrete, and foster the circular economy. Leveraging its global manufacturing presence, Saint-Gobain Construction Chemicals serves its customers through local sites in over 40 countries, employing over 2,700 people.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005807/en/
Contact information
Press relations
CHRYSO
Daphnée DECAUDIN
Daphnee.decaudin@chryso.com
+33 6 19 07 64 74
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
